Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · Real-Time Price · USD
3.870
+0.010 (0.26%)
At close: Nov 20, 2024, 4:00 PM
3.690
-0.180 (-4.65%)
After-hours: Nov 20, 2024, 7:44 PM EST
Company Description
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States.
The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors.
It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Kevin Richardson |
Contact Details
Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States | |
| Phone | 760 452 8111 |
| Website | qlgntx.com |
Stock Details
| Ticker Symbol | QLGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001460702 |
| CUSIP Number | 74754R103 |
| ISIN Number | US74754R2022 |
| Employer ID | 26-3474527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin A. Richardson II | Interim Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board |
| Michael S. Poirier | Chief Operating Officer |
| Robert W. Campbell Becher | President and Independent Director |
| Christopher L. Lotz | Vice President of Finance and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 24, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 9, 2024 | 8-K | Current Report |
| Oct 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 26, 2024 | 8-K | Current Report |